Alumis Inc. (ALMS) has a MoatMap StockRank of 31/100 based on Quality (25/100), Value (33/100), and Momentum (61/100) factor scores. The current signal is HOLD. As a biotechnology company, Alumis Inc. typically involves binary R&D outcomes, high capital requirements, and lacks the immediate asset-light, durable moat, and predictable cash flow characteristics favored by the investment philosophy, making it too speculative without specific drug pipeline analysis.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral therapies for patients suffering from immune-mediated diseases. The company's competitive moat is built upon its proprietary drug discovery platform and a focused pipeline targeting specific immunological pathways with high unmet medical needs. It aims to differentiate through innovative treatments for chronic inflammatory conditions.
| Price | $21.40 |
| Market Cap | $2.7B |
| P/E (Forward) | -7.56 |
| Price/Book | 5.01 |
| Return on Equity | -64.6% |
| Return on Invested Capital | -134.0% |
| Debt/Equity | 6.29 |
| Gross Margin | 100.0% |
| Operating Margin | -5652.4% |
| Revenue Growth | -90.0% |
| Free Cash Flow | $-207M |
Alumis Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).